Notification of change in exposure among primary insiders

Today insider Atul Shah through his related company acquired 50 % of Capveen AS, which prior to this transaction was 100 % owned by insider Praveen Sharma and his close associate.  This transaction changes the individual exposures for Praveen Sharma and Atul Shah.

Capveen AS owns 2,662,128 shares in DiaGenic. In addition Sharma owns 2,490,764 shares in DiaGenic and Shah owns indirectly through his related company 5,061,040 shares in DiaGenic. This transaction in Capveen AS does not involve any transaction in DiaGenic shares.

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

e-mail: erik.christensen@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com